The SUOX gene encodes sulfite oxidase, a vital mitochondrial enzyme responsible for converting sulfite to sulfate, the final step in degrading sulfur-containing amino acids such as cysteine and methionine.
This process prevents toxic sulfite accumulation, protecting cells from oxidative damage.
Each subunit of sulfite oxidase has a heme domain and a molybdopterin-binding domain, requiring molybdenum and iron as cofactors.
Deficiencies in sulfite oxidase, caused by mutations in the SUOX gene, lead to severe neurological disorders, including isolated sulfite oxidase deficiency, characterized by developmental delays, seizures, and early mortality.
Additionally, genetic variations in SUOX have been linked to conditions like polycystic ovarian syndrome (PCOS), highlighting its role in various health conditions and the importance of genetic testing in understanding disease susceptibility.
The SUOX gene encodes the enzyme sulfite oxidase, a protein located in the intermembrane space of mitochondria. Each subunit of this enzyme contains a heme domain and a molybdopterin-binding domain.
The SUOX enzyme requires molybdenum and iron as cofactors. [1.]
Sulfite oxidase catalyzes the oxidation of sulfite to sulfate, which is the final step in the oxidative degradation of sulfur-containing amino acids such as cysteine and methionine. This reaction is essential for preventing the accumulation of toxic sulfite levels in the body.
Deficiency in sulfite oxidase leads to severe neurological abnormalities that are often fatal early in life.
Genetic changes in the SUOX gene are related to health conditions such as isolated sulfite oxidase deficiency and polycystic ovarian syndrome. [6.]
By converting sulfite to sulfate, which is then excreted in urine, SUOX plays a crucial role in maintaining sulfur amino acid homeostasis and protecting cells from oxidative damage caused by sulfite accumulation.
Mutations or defects in the SUOX gene can lead to a condition known as sulfite oxidase deficiency, which is characterized by neurological abnormalities, developmental delay, and in severe cases, early infant mortality.
SUOX gene mutations disrupt the normal function of the enzyme, leading to the buildup of sulfite and other toxic intermediates that can cause significant cellular damage, particularly in the brain.
At least 27 mutations in the SUOX gene have been identified.
Ectopia lentis refers to the displacement or dislocation of the eye's crystalline lens from its normal position.
This condition can affect one or both eyes and may occur due to developmental issues, trauma, or underlying genetic or metabolic disorders. It is associated with Isolated Sulfite Oxidase Deficiency. [2.]
PCOS is known to have a complex genetic basis involving multiple genes and environmental factors. SUOX is just one of many genes that have been associated with PCOS risk in various studies.
One study that linked altered SUOX function with PCOS investigates the link between specific single nucleotide polymorphisms (SNPs) and polycystic ovary syndrome (PCOS) in Han Chinese women. [4.]
The case-control study compared 285 women with PCOS to 299 healthy controls, focusing on SNPs identified in previous genome-wide association studies (GWAS). It found that the SNP rs705702 in the RAB5B/SUOX gene was significantly associated with an increased risk of PCOS. [4.]
The genotypic analysis also supported this association, suggesting that rs705702 increases PCOS susceptibility in this population.
Additional research implicates the SUOX gene as one piece of a much larger puzzle in the pathogenesis of PCOS involving fetal development and growth, as well as various organs and systems beyond the ovaries. [3.]
The SUOX gene, among others, is dynamically expressed in various tissues during fetal development.
This gene, involved in enzymatic reactions, shows varied expression patterns across different tissues, including gonadal, metabolic, and brain tissues, during early to mid-gestation and postnatally until adulthood.
The findings of one research suggest that the SUOX gene, along with other PCOS candidate genes, may have tissue-specific and developmental stage-specific roles, potentially contributing to the various symptoms associated with PCOS. [3.]
The results of this study support the theory that the predisposition to PCOS originates during fetal development and affects multiple organ systems, not just the ovaries. [3.]
The gene for the SUOX protein may contain alterations or mutations that cause increase or decrease of function of the SUOX protein.
Testing for genetic alterations in the form of SNPs is increasingly available and can shed light on an individual’s potential for health and disease.
A SNP, or single nucleotide polymorphism, refers to a variation at a single position in a gene along its DNA sequence. A gene encodes a protein, so an alteration in that gene programs the production of an altered protein.
As a type of protein with great functionality in human health, alterations in genes for enzymes may confer a difference in function of that enzyme. The function of that enzyme may be increased or decreased, depending on the altered protein produced.
SNPs are the most common type of genetic variation in humans and can occur throughout the genome, influencing traits, susceptibility to diseases, and response to medications.
The completion of the Human Genome Project has significantly expanded opportunities for genetic testing by providing a comprehensive map of the human genome that facilitates the identification of genetic variations associated with various health conditions, including identifying SNPs that may cause alterations in protein structure and function.
Genetic testing for SNPs enables the identification of alterations in genes, shedding light on their implications in health and disease susceptibility.
Genetic testing for single nucleotide polymorphisms (SNPs) typically involves obtaining a sample of DNA which can be extracted from blood, saliva, or cheek swabs.
The sample may be taken in a lab, in the case of a blood sample. Alternatively, a saliva or cheek swab sample may be taken from the comfort of home.
Prior to undergoing genetic testing, it's important to consult with a healthcare provider or genetic counselor to understand the purpose, potential outcomes, and implications of the test. This consultation may involve discussing medical history, family history, and any specific concerns or questions.
Additionally, individuals may be advised to refrain from eating, drinking, or chewing gum for a short period before providing a sample to ensure the accuracy of the test results. Following sample collection, the DNA is processed in a laboratory where it undergoes analysis to identify specific genetic variations or SNPs.
Once the testing is complete, individuals will typically receive their results along with interpretation and recommendations from a healthcare professional.
It's crucial to approach genetic testing with proper understanding and consideration of its implications for one's health and well-being.
A patient-centered approach to SNP genetic testing emphasizes individualized medicine, tailoring healthcare decisions and interventions based on an individual's unique genetic makeup.
When that is combined with the individual’s health status and health history, preferences, and values, a truly individualized plan for care is possible.
By integrating SNP testing into clinical practice, healthcare providers can offer personalized risk assessment, disease prevention strategies, and treatment plans that optimize patient outcomes and well-being.
Genetic testing empowers a deeper understanding of genetic factors contributing to disease susceptibility, drug response variability, and overall health, empowering patients to actively participate in their care decisions.
Furthermore, individualized medicine recognizes the importance of considering socioeconomic, cultural, and environmental factors alongside genetic information to deliver holistic and culturally sensitive care that aligns with patients' goals and preferences.
Through collaborative decision-making and shared decision-making processes, patients and providers can make informed choices about SNP testing, treatment options, and lifestyle modifications, promoting patient autonomy, engagement, and satisfaction in their healthcare journey.
Integrating multiple biomarkers into panels or combinations enhances the predictive power and clinical utility of pharmacogenomic testing. Biomarker panels comprising a variety of transporter proteins and enzymes including drug metabolizing enzymes offer comprehensive insights into individual drug response variability and treatment outcomes.
Combining genetic SNP testing associated with drug transport, metabolism, and pharmacodynamics enables personalized medicine approaches tailored to individual patient characteristics and genetic profiles.
Click here to compare genetic test panels and order genetic testing for health-related SNPs.
Hey Practitioners! Want to learn from New York Times best-selling author Dr. Casey Means? In this upcoming free live class for practitioners, Dr. Means will teach us about the clinical importance of understanding metabolic health in every patient, how to test for it, and key dietary and lifestyle changes that can start to improve it. Sign up here!
[1.] Karakas E, Kisker C. Structural analysis of missense mutations causing isolated sulfite oxidase deficiency. Dalton Trans. 2005 Nov 7;(21):3459-63. doi: 10.1039/b505789m. Epub 2005 Sep 26. PMID: 16234925.
[2.] Li JT, Chen ZX, Chen XJ, Jiang YX. Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation. Orphanet J Rare Dis. 2022 Oct 27;17(1):392. doi: 10.1186/s13023-022-02544-x. PMID: 36303223; PMCID: PMC9615255.
[3.] Rafiatu Azumah, Katja Hummitzsch, Anderson RA, Rodgers RJ. Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues. Frontiers in endocrinology. 2023;14. doi:https://doi.org/10.3389/fendo.2023.1149473
[4.] Sun Y, Yuan Y, Yang H, Li J, Feng T, Ouyang Y, Jin T, Liu M. Association between Common Genetic Variants and Polycystic Ovary Syndrome Risk in a Chinese Han Population. J Clin Res Pediatr Endocrinol. 2016 Dec 1;8(4):405-410. doi: 10.4274/jcrpe.2784. Epub 2016 May 23. PMID: 27217259; PMCID: PMC5197998.
[5.] SUOX sulfite oxidase [Homo sapiens (human)] - Gene - NCBI. www.ncbi.nlm.nih.gov. https://www.ncbi.nlm.nih.gov/gene/6821
[6.] SUOX gene: MedlinePlus Genetics. medlineplus.gov. https://medlineplus.gov/genetics/gene/suox/#conditions